SCHEMBL30291340

SCHEMBL30291340

O=C1CCC(n2nnc3ccc(F)cc3c2=O)C(=O)N1

nearest known ligand 0.57

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 19/20 0.57
DDB1 Q16531 15/20 0.50
IKZF3 Q9UKT9 4/20 0.42
ALDH1A1 P00352 1/20 0.39
CHRM2 P08172 1/20 0.39
OPRM1 P35372 1/20 0.39
CYP1A2 P05177 1/20 0.39
TSHR P16473 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
TNF P01375 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24233170 1.00 CRBN (0.57) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL25571846 0.91 CRBN (0.65) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL21751118 0.87 CRBN (0.55) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL21751104 0.86 CRBN (0.54) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL21751098 0.86 CRBN (0.56) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL29791185 0.86 CRBN (0.57) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL21751067 0.86 CRBN (0.54) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL23534466 0.86 CRBN (0.57) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL30241763 0.86 CRBN (0.56) CRBNDDB1IKZF3ALDH1A1CHRM2
SCHEMBL25653897 0.85 CRBN (0.52) CRBNDDB1IKZF3ALDH1A1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119684303-A Heterocyclic compound of difunctional degradable androgen receptor and application thereof 上海超阳药业有限公司 2025-03-25 CN disclosed
CN-116157390-A Compounds for androgen receptor degradation and pharmaceutical uses thereof 尤比克斯治疗公司 2023-05-23 CN disclosed
WO-2023039603-A2 BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR MONTELINO THERAPEUTICS, INC. (US) 2023-03-16 WO disclosed